| Robert, Francisco |
NCT04137900: Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies |
|
|
| Recruiting | 1 | 499 | US | TAB004, JS004, Toripalimab, TAB001, JS001 | TopAlliance Biosciences, Shanghai Junshi Bioscience Co., Ltd., CTI Clinical Trial and Consulting Services | Advanced Unresectable Solid Tumor, Metastatic Solid Tumor | 03/26 | 03/26 | | |
| Nabell, Lisle M |
| Active, not recruiting | 2 | 171 | Europe, US, RoW | eftilagimod alpha, IMP321, efti, eftilagimod alfa, pembrolizumab (KEYTRUDA®), MK-3475 | Immutep S.A.S., Merck Sharp & Dohme LLC | HNSCC | 03/24 | 03/25 | | |
|
| Active, not recruiting | 1/2 | 200 | Europe, US | HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C) | Hookipa Biotech GmbH, Hookipa Biotech | HPV-Related Squamous Cell Carcinoma | 06/25 | 06/26 | | |
| Recruiting | 1 | 438 | Europe, Canada, US | PF-08046054, SGN-PDL1V, pembrolizumab, Keytruda | Seagen Inc. | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Melanoma, Triple Negative Breast Neoplasms, Gastric Cancer | 07/25 | 12/27 | | |
| Carroll, William |
NCT01017055: Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery |
|
|
| Recruiting | N/A | 200 | US | Voice and Swallowing evaluations | University of Alabama at Birmingham | Dysphagia, Dysphonia | 12/25 | 06/26 | | |
| McConathy, Jonathan |
| Recruiting | 2 | 160 | US | [C-11]PiB-PET/MRI | University of Alabama at Birmingham, National Institute on Aging (NIA) | Alzheimer Disease | 04/26 | 04/26 | | |
NCT03457493: The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy |
|
|
| Recruiting | 1/2 | 205 | US | DPA-714-PET/MRI, 5-year Follow-up DPA-714-PET/MRI, DPA-714 Metabolite Analysis | University of Alabama at Birmingham | Parkinson Disease | 06/27 | 06/27 | | |
NCT05285696: Study to Evaluate the Safety and Dosimetry of [68Ga]-NOTA-hGZP (CSB-111) PET Imaging in Healthy Human Volunteers. |
|
|
| Completed | 1 | 6 | US | CSB-111, [68Ga]-NOTA-hGZP | Cytosite Biopharma Inc., University of Alabama at Birmingham | Healthy Volunteers | 04/23 | 05/23 | | |
NCT03759522: Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. |
|
|
| Recruiting | 1 | 120 | US | DPA-714 PET/MRI | University of Alabama at Birmingham | Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy | 04/26 | 04/26 | | |
NCT03451123: FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors |
|
|
| Terminated | 1 | 1 | US | FET PET/MRI | University of Alabama at Birmingham | Pediatric Brain Tumors | 08/23 | 08/23 | | |
NCT06289582: Longitudinal TSPO PET Imaging with [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging) |
|
|
| Recruiting | 1 | 60 | US | [F-18]DPA714 administration IV | University of Alabama at Birmingham, Michael J. Fox Foundation for Parkinson's Research | Parkinson Disease | 06/27 | 06/27 | | |
NCT03807973: Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. |
|
|
| Recruiting | 1 | 120 | US | [Zr-89]Oxine-labeled leukocytes PET/MRI | University of Alabama at Birmingham | Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy | 10/28 | 10/28 | | |
NCT03968445: Neuroinflammation After Myocardial Infarction - Imaging Substudy |
|
|
| Active, not recruiting | 1 | 6 | US | [18F]DPA-714-PET/MRI | University of Alabama at Birmingham | Myocardial Infarction | 10/28 | 10/28 | | |
NCT05238961: Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy |
|
|
| Recruiting | 1 | 20 | US | [18F]DPA-714 | University of Alabama at Birmingham | Critical Asymptomatic Carotid Artery Disease, Non-Critical Asymptomatic Carotid Artery Disease | 12/27 | 12/27 | | |
NCT04364672: Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer |
|
|
| Withdrawn | 1 | 20 | NA | 18F-labeled DPA-714 PET scan | University of Alabama at Birmingham | Breast Cancer | 07/26 | 07/26 | | |
NCT04332588: Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI |
|
|
| Recruiting | 1 | 25 | US | [18F]FMISO PET/MRI imaging | University of Alabama at Birmingham | HER2-positive Breast Cancer | 08/27 | 08/27 | | |
NCT04169321: Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors |
|
|
| Recruiting | 1 | 30 | US, RoW | Single Arm, [68Ga]-NOTA-hGZP, CSB-111 | Cytosite Biopharma Inc., Massachusetts General Hospital, University of Alabama at Birmingham, Chang Gung Memorial Hospital | Solid Tumor, Unspecified, Adult, Lymphoma | 12/25 | 02/26 | | |
NCT05656105: Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients with Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection |
|
|
| Recruiting | 1 | 60 | US | DPA-714 PET/MRI | University of Alabama at Birmingham | SARS CoV-2 Post-Acute Sequelae | 06/26 | 06/26 | | |
NCT04542603: Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer |
|
|
| Withdrawn | 1 | 20 | NA | [11C]PiB and 18F-labeled DPA-714 PET scan | University of Alabama at Birmingham | Ovarian Cancer | 08/26 | 08/26 | | |
NCT05632562: Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma |
|
|
| Recruiting | 1 | 20 | US | O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI | University of Alabama at Birmingham | High Grade Glioma | 02/26 | 02/26 | | |
NCT05676489: MeFAMP for Imaging System a Amino Acid Transport in Primary and Metastatic Brain Tumors |
|
|
| Not yet recruiting | 1 | 28 | US | [F-18]MeFAMP PET | University of Alabama at Birmingham | Healthy Volunteers, Recurrent Glioma, Brain Metastases from Extra-cranial Solid Tumors | 08/27 | 08/27 | | |
| Yang, Eddy |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NRG-HN006, NCT04333537: Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer |
|
|
| Recruiting | 2/3 | 618 | Canada, US | Computed Tomography (CT), CAT, CAT scan, Computed Tomography, computerized axial tomography, Computerized Tomography, CT, CT scan, tomography, Imaging Agent, Image Enhancement Agent, Neck Dissection, Planar Imaging, Sentinel Lymph Node Biopsy, Sentinel Node Biopsy, Sentinel node biopsy alone, SLNB, SNB, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon | NRG Oncology, National Cancer Institute (NCI) | Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma | 05/31 | 05/36 | | |
| Active, not recruiting | 2 | 114 | US | Olaparib, AZD2281, KU-0059436 | Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute | Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation | 07/25 | 12/25 | | |
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer |
|
|
| Recruiting | 2 | 3791 | US | Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi | American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc. | Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors | 06/26 | 06/27 | | |
RAD 1805, NCT04298983: Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer |
|
|
| Active, not recruiting | 2 | 9 | US | Abemaciclib 150 MG by mouth twice daily, Androgen deprivation therapy (ADT), Radiation Therapy | University of Alabama at Birmingham | Prostate Cancer | 04/25 | 04/26 | | |
NCT05283330: Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors |
|
|
| Recruiting | 1 | 30 | US | ²¹²Pb-DOTAM-GRPR1 | Orano Med LLC | Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma | 08/24 | 01/25 | | |
| Recruiting | N/A | 5000 | Europe, Canada, US, RoW | Standard of Care | Prostate Cancer Clinical Trials Consortium | Prostate Cancer | 01/31 | 01/32 | | |
| Bhambhvani, Pradeep |
NCT04364672: Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer |
|
|
| Withdrawn | 1 | 20 | NA | 18F-labeled DPA-714 PET scan | University of Alabama at Birmingham | Breast Cancer | 07/26 | 07/26 | | |
NCT04542603: Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer |
|
|
| Withdrawn | 1 | 20 | NA | [11C]PiB and 18F-labeled DPA-714 PET scan | University of Alabama at Birmingham | Ovarian Cancer | 08/26 | 08/26 | | |
NCT04795856: Understanding the Metabolic and Functional Derangement of Primary Mitral Regurgitation: a Feasibility Study Using Carbon 11(C-11) Acetate Cardiac Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI) |
|
|
| Not yet recruiting | 1 | 12 | US | [11C] acetate | University of Alabama at Birmingham | Mitral Valve Regurgitation | 08/28 | 08/28 | | |
| O'Malley, Janis P |
NCT04332588: Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI |
|
|
| Recruiting | 1 | 25 | US | [18F]FMISO PET/MRI imaging | University of Alabama at Birmingham | HER2-positive Breast Cancer | 08/27 | 08/27 | | |
NCT04861077: Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) |
|
|
| Not yet recruiting | 1 | 20 | US | [18F]FMISO-PET with contrast-enhanced MRI | University of Alabama at Birmingham | Triple Negative Breast Cancer | 08/26 | 08/27 | | |
| Choudhary, Gagandeep |
NCT04364672: Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer |
|
|
| Withdrawn | 1 | 20 | NA | 18F-labeled DPA-714 PET scan | University of Alabama at Birmingham | Breast Cancer | 07/26 | 07/26 | | |
NCT04542603: Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer |
|
|
| Withdrawn | 1 | 20 | NA | [11C]PiB and 18F-labeled DPA-714 PET scan | University of Alabama at Birmingham | Ovarian Cancer | 08/26 | 08/26 | | |
| Conry, Marty |
| No trials found |
| Galgano, Sam |
| No trials found |
| White, Sharon |
| No trials found |
| Lapi, Suzy |
| No trials found |
